Drug Trial Radar · NCT03268005
Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Jan 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,264
Actual
Start
Sep 19, 2017
Primary completion
Jan 7, 2019
Study completion Jan 29, 2019
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Aug 31, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study compares 2 medicines for type 2 diabetes: fast-acting insulin aspart (a new medicine) and NovoRapid®/NovoLog® (a medicine doctors can already prescribe). Fast-acting insulin aspart will be tested to see how well it works and if it is safe. Participants will get either fast-acting insulin aspart or NovoRapid®/ NovoLog® - which treatment you get is decided by chance. Both medicines will be taken together with insulin degludec. Participants will need to take 1 injection 4 times every day (all insulins will be provided in pens). The study will last for about 8 months (34 weeks).
Conditions
- Diabetes
- Diabetes Mellitus, Type 2
Interventions
Faster-acting insulin aspartDrug
Faster aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
Insulin aspartDrug
Insulin aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
Insulin degludecDrug
Insulin degludec given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
MetforminDrug
Only participants who took metformin before the study should take metformin tablets, same dose as before the study
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Glycosylated Haemoglobin (HbA1c)Time frame: Week 0, week 16
Locations
167 sites in 18 countries. Site status is shown where the registry gives one.
Novo Nordisk Investigational Site
Concord, California
Novo Nordisk Investigational Site
Fresno, California
Novo Nordisk Investigational Site
Fullerton, California
Novo Nordisk Investigational Site
Lancaster, California
Novo Nordisk Investigational Site
Norco, California
Novo Nordisk Investigational Site
Sacramento, California
Novo Nordisk Investigational Site
Ventura, California
Novo Nordisk Investigational Site
Walnut Creek, California
Novo Nordisk Investigational Site
Denver, Colorado
Novo Nordisk Investigational Site
Golden, Colorado
Novo Nordisk Investigational Site
Waterbury, Connecticut
Novo Nordisk Investigational Site
Boynton Beach, Florida
Novo Nordisk Investigational Site
Bradenton, Florida
Novo Nordisk Investigational Site
Fort Lauderdale, Florida
Novo Nordisk Investigational Site
Miami, Florida
Novo Nordisk Investigational Site
Tampa, Florida
Novo Nordisk Investigational Site
Alpharetta, Georgia
Novo Nordisk Investigational Site
Lawrenceville, Georgia
Novo Nordisk Investigational Site
Roswell, Georgia
Novo Nordisk Investigational Site
Honolulu, Hawaii
Novo Nordisk Investigational Site
Chicago, Illinois
Novo Nordisk Investigational Site
Peoria, Illinois
Novo Nordisk Investigational Site
Springfield, Illinois
Novo Nordisk Investigational Site
Valparaiso, Indiana
Novo Nordisk Investigational Site
West Des Moines, Iowa
Novo Nordisk Investigational Site
Topeka, Kansas
Novo Nordisk Investigational Site
Lexington, Kentucky
Novo Nordisk Investigational Site
Lexington, Kentucky
Novo Nordisk Investigational Site
Rockville, Maryland
Novo Nordisk Investigational Site
Waltham, Massachusetts
Novo Nordisk Investigational Site
Worcester, Massachusetts
Novo Nordisk Investigational Site
Henderson, Nevada
Novo Nordisk Investigational Site
Las Vegas, Nevada
Novo Nordisk Investigational Site
Nashua, New Hampshire
Novo Nordisk Investigational Site
Northport, New York
Novo Nordisk Investigational Site
West Seneca, New York
Novo Nordisk Investigational Site
Asheville, North Carolina
Novo Nordisk Investigational Site
Chapel Hill, North Carolina
Novo Nordisk Investigational Site
Mentor, Ohio
Novo Nordisk Investigational Site
Oklahoma City, Oklahoma
Showing 40 of 167 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.